Clinical Trial

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Summary
This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-08.
Status change: Active, Not Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07164885
Lead Sponsor Capital Medical University
Conditions Locally Advanced Non-small Cell Lung Cancer
Enrollment 911 participants
Start Date 2025-02-17
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-02